{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:43:29Z","timestamp":1793717009257,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013668","name":"Cancer Focus Northern Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001592","name":"Higher Education Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcpo.2024.100468","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T11:44:32Z","timestamp":1706874272000},"page":"100468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Skin in the game: The cost consequences of skin cancer diagnosis, treatment and care in Northern Ireland"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-7822","authenticated-orcid":false,"given":"Ethna","family":"McFerran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2024.100468_bib1","unstructured":"Public Health England. Factors Influencing Survival from Melanoma in England, Northern Ireland, and Scotland,\u00a02015."},{"key":"10.1016\/j.jcpo.2024.100468_bib2","unstructured":"Cancer Research UK. Melanoma skin cancer statistics. Published 2023. Accessed January 11, 2023. \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/melanoma-skin-cancer\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib3","unstructured":"Global Coalition for Melanoma Patient Advocacy, Euro Melanoma. 2020 Melanoma Skin Cancer Report- Stemming the Global Epidemic. Published online 2020:16."},{"issue":"7","key":"10.1016\/j.jcpo.2024.100468_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-20-0098","article-title":"Cancer incidence projections in Northern Ireland to 2040","volume":"29","author":"Donnelly","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"9","key":"10.1016\/j.jcpo.2024.100468_bib5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jid.2017.04.020","article-title":"Incidence, mortality, and trends of nonmelanoma skin cancer in Germany","volume":"137","author":"Leiter","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jcpo.2024.100468_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10198-008-0127-0","article-title":"Cost of skin cancer in England","volume":"10","author":"Morris","year":"2009","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"10.1016\/j.jcpo.2024.100468_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/pubmed\/fdt032","article-title":"Measuring current and future cost of skin cancer in England","volume":"36","author":"Vallejo-Torres","year":"2014","journal-title":"J. Public Health (U. Kingd. )"},{"key":"10.1016\/j.jcpo.2024.100468_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/bjd.15110","article-title":"Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology","volume":"176","author":"Goon","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jcpo.2024.100468_bib9","doi-asserted-by":"crossref","unstructured":"Rice D.P. Cost of illness studies: what is good about them? \u3008doi:10.1136\/ip.6.3.177\u3009.","DOI":"10.1136\/ip.6.3.177"},{"key":"10.1016\/j.jcpo.2024.100468_bib10","unstructured":"Skin Cancer Prevention Strategy and Action Plan 2011 -2021, 2011."},{"key":"10.1016\/j.jcpo.2024.100468_bib11","unstructured":"NHS England\u00a0\" 2021\/22 National Cost Collection Data Publication. Accessed December 19, 2023. \u3008https:\/\/www.england.nhs.uk\/publication\/2021\u201322-national-cost-collection-data-publication\/\u3009."},{"issue":"4","key":"10.1016\/j.jcpo.2024.100468_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","article-title":"Cost-of-illness studies: concepts, scopes, and methods","volume":"20","author":"Jo","year":"2014","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.jcpo.2024.100468_bib13","unstructured":"National Institute for Health and Care Excellence (NICE). Melanoma: Overview, 2015."},{"key":"10.1016\/j.jcpo.2024.100468_bib14","unstructured":"United Kingdom and Ireland Association of Cancer Registries (UKIACR). United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2017.; 2021."},{"issue":"17","key":"10.1016\/j.jcpo.2024.100468_bib15","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.12968\/bjon.2019.28.17.S10","article-title":"Understanding a sentinel lymph node biopsy service for patients with malignant melanoma","volume":"28","author":"Stothers","year":"2019","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.jcpo.2024.100468_bib16","unstructured":"Filby A. NICE An Economic Evaluation of Interventions to Improve the Uptake of Vitamin D Supplements in England and Wales Report."},{"key":"10.1016\/j.jcpo.2024.100468_bib17","unstructured":"National Institute for Health and Care Excellence (NICE). Guideline Melanoma: assessment and management. Published 2022. Accessed September 20, 2022. \u3008https:\/\/www.nice.org.uk\/guidance\/ng14\/update\/ng14-update-1\/documents\/draft-guideline-4\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib18","unstructured":"Hospital Admitted Patient Care Activity, 2021\u201322 - NHS Digital. Accessed December 19, 2023. \u3008https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/hospital-admitted-patient-care-activity\/2021\u201322\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib19","first-page":"1","article-title":"Cost consequences of unscheduled emergency admissions in cancer patients in the last year of life","volume":"31","author":"McFerran","year":"2022","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jcpo.2024.100468_bib20","unstructured":"Bannon F. Pathways to a Cancer Diagnosis: Monitoring Variation in the Patient Journey across Northern Ireland.; 2020. Accessed April 27, 2021. \u3008http:\/\/www.hscbusiness.hscni.net\/pdf\/Routes\u3009 to Diagnosis Report - Main Report Jan 2020.pdf."},{"issue":"10","key":"10.1016\/j.jcpo.2024.100468_bib21","first-page":"1167","article-title":"Evaluation of the number-needed-to-biopsy metric for the diagnosis of cutaneous melanoma a systematic review and meta-analysis","volume":"77030","author":"Nelson","year":"2019"},{"issue":"4","key":"10.1016\/j.jcpo.2024.100468_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bjd.18884","article-title":"A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherla.","volume":"183","author":"Jansen","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jcpo.2024.100468_bib23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/bjd\/ljac090","article-title":"The epidemiology, healthcare, and societal burden of basal cell carcinoma in Wales 2000-2018: a retrospective nationwide analysis.","volume":"188","author":"Ibrahim","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.jcpo.2024.100468_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/13696998.2016.1184155","article-title":"Cost, and economic burden of adverse events associated with metastatic melanoma treatments in five countries.","volume":"19","author":"Vouk","year":"2016","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.jcpo.2024.100468_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CMR.0000000000000158","article-title":"The cost of ipilimumab toxicity: a single-centre analysis","volume":"25","author":"Yousaf","year":"2014","journal-title":"Melanoma Res."},{"issue":"31","key":"10.1016\/j.jcpo.2024.100468_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011736","article-title":"Direct costs associated with adverse events of systemic therapies for advanced melanoma Systematic literature review","volume":"97","author":"Copley-Merriman","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.jcpo.2024.100468_bib27","article-title":"Systematic or Meta-analysis Studies Immune checkpoint Inhibitor-Induced diarrhea and colitis: incidence and management. A systematic review and Meta-analysis","volume":"109","author":"Lisbet Nielsen","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.jcpo.2024.100468_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjd.21046","article-title":"Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning*","volume":"187","author":"Eden","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jcpo.2024.100468_bib29","doi-asserted-by":"crossref","unstructured":"Boutros A., Cecchi F., Teresa Tanda E., et al. Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma. \u3008doi:10.3389\/fonc.2021.733917\u3009.","DOI":"10.3389\/fonc.2021.733917"},{"key":"10.1016\/j.jcpo.2024.100468_bib30","unstructured":"N.H.S. England\u00a0\" 2021\/22 National Cost Collection Data Publication. Accessed December 19, 2023. \u3008https:\/\/www.england.nhs.uk\/publication\/2021\u201322-national-cost-collection-data-publication\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib31","unstructured":"NHS Northampton General Hospital Trust. NGH launches a new treatment for early skin cancers. Published 2012. Accessed March 8, 2023. \u3008https:\/\/www.northamptongeneral.nhs.uk\/News\/Articles\/AllNews\/NGH-launches-a-new-treatment-for-early-skin-cancers.aspx\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib32","unstructured":"National Cancer Registration and Analysis Service. Cancer Waiting Times (CWT) urgent suspected cancer referrals: referral, conversion, and detection rates. Published 2022. Accessed September 16, 2022. \u3008https:\/\/www.cancerdata.nhs.uk\/cwt_conversion_and_detection\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib33","unstructured":"Jones K., Weatherly H., Castelli A., et al. Unit Costs of Health and Social Care 2022 Manual."},{"key":"10.1016\/j.jcpo.2024.100468_bib34","unstructured":"Medicinal forms | Imiquimod | Drugs | BNF | NICE. Accessed December 21, 2023. \u3008https:\/\/bnf.nice.org.uk\/drugs\/imiquimod\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib35","article-title":"Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentary","volume":"87","author":"Mc Partlin","year":"2014","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.jcpo.2024.100468_bib36","unstructured":"British Association of Dermatologists. Accessed December 21, 2023. \u3008https:\/\/www.bad.org.uk\/pils\/5-fluorouracil-cream\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib37","unstructured":"Medicinal forms | Fluorouracil | Drugs | BNF | NICE. Accessed December 21, 2023. \u3008https:\/\/bnf.nice.org.uk\/drugs\/fluorouracil\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jcpo.2024.100468_bib39","unstructured":"National Institute for Health and Care Excellence (NICE). Medicinal forms _ Pembrolizumab _ Drugs _ BNF _ NICE. Published 2019. Accessed September 16, 2019. \u3008https:\/\/bnf.nice.org.uk\/drugs\/pembrolizumab\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib40","unstructured":"National Institute for Health and Care Excellence (NICE). Medicinal forms _ Nivolumab _ Drugs _ BNF _ NICE. Published 2019. Accessed September 16, 2019. \u3008https:\/\/bnf.nice.org.uk\/drugs\/nivolumab\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib41","unstructured":"National Institute for Health and Care Excellence (NICE). Medicinal forms _ Ipilimumab _ Drugs _ BNF _ NICE. Published 2019. Accessed September 16, 2019. \u3008https:\/\/bnf.nice.org.uk\/drugs\/ipilimumab\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib42","unstructured":"National Institute for Health and Care Excellence (NICE). Medicinal forms _ Dabrafenib _ Drugs _ BNF _ NICE. Published 2019. Accessed September 16, 2019. \u3008https:\/\/bnf.nice.org.uk\/drugs\/dabrafenib\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib43","unstructured":"National Institute for Health and Care Excellence (NICE). Medicinal forms _ Trametinib _ Drugs _ BNF _ NICE. Accessed September 16, 2019. \u3008https:\/\/bnf.nice.org.uk\/drugs\/trametinib\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib44","unstructured":"Medicinal forms _ Binimetinib _ Drugs _ BNF _ NICE. Published 2019. Accessed September 16, 2019. \u3008https:\/\/bnf.nice.org.uk\/drugs\/binimetinib\/medicinal-forms\/\u3009."},{"key":"10.1016\/j.jcpo.2024.100468_bib45","first-page":"1","article-title":"Cancer treatment helpline: a retrospective study of the NHS Tayside experience","author":"Trip","year":"2021","journal-title":"BMJ Open Qual."},{"key":"10.1016\/j.jcpo.2024.100468_bib46","doi-asserted-by":"crossref","unstructured":"L.Y. Lin L. Smeeth S. Langan C. Warren, Distribution of vitamin D status in the sectional analysis of UK: a cross- UK Biobank. Published online 2021:1\u20138. doi:10.1136\/bmjopen-2020\u2013038503.","DOI":"10.1136\/bmjopen-2020-038503"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221353832400002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221353832400002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:07:39Z","timestamp":1761988059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221353832400002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"alternative-id":["S221353832400002X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100468","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.05.09.23289720","asserted-by":"object"}]},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin in the game: The cost consequences of skin cancer diagnosis, treatment and care in Northern Ireland","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100468"}}